However, given the presence of chronic low-level inflammation, as well as the associated obesity, insulin resistance, hypertriacylglyceridemia, and its positive correlation with the development of pancreatitis [136], which is a risk factor for pancreatic cancer, patients in this group should exercise particular caution when using GLP-1 analogs and undergo regular monitoring. This evidence concerns the gene GLP1R and pancreatitis.